1. Home
  2. OFIX vs FULC Comparison

OFIX vs FULC Comparison

Compare OFIX & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orthofix Medical Inc. (DE)

OFIX

Orthofix Medical Inc. (DE)

HOLD

Current Price

$9.86

Market Cap

473.3M

Sector

Health Care

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.74

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OFIX
FULC
Founded
1987
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
473.3M
467.8M
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
OFIX
FULC
Price
$9.86
$3.74
Analyst Decision
Buy
Buy
Analyst Count
5
8
Target Price
$17.25
$16.38
AVG Volume (30 Days)
402.5K
3.8M
Earning Date
05-05-2026
04-27-2026
Dividend Yield
N/A
N/A
EPS Growth
29.39
N/A
EPS
N/A
N/A
Revenue
$822,312,000.00
N/A
Revenue This Year
$6.13
N/A
Revenue Next Year
$6.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.85
N/A
52 Week Low
$8.85
$2.83
52 Week High
$16.99
$15.74

Technical Indicators

Market Signals
Indicator
OFIX
FULC
Relative Strength Index (RSI) 50.49 38.11
Support Level $8.99 $2.83
Resistance Level $9.90 $4.02
Average True Range (ATR) 0.45 0.22
MACD 0.12 0.14
Stochastic Oscillator 88.39 54.70

Price Performance

Historical Comparison
OFIX
FULC

About OFIX Orthofix Medical Inc. (DE)

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: